Logo

Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis

1, 2, 3, 4

  1. Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland. sanna.leinonen@hus.fi
  2. Department of Paediatrics, University of Helsinki, Helsinki University Hospital, Finland.
  3. Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland.
  4. Department of Ophthalmology, University of Helsinki, Helsinki University Hospital, Finland.

CER9793 Submission on line
2017 Vol.35, N°6 - PI 1043, PF 1046
Paediatric Rheumatology

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

Abstract

OBJECTIVES:
To evaluate the association of adalimumab trough levels and anti-adalimumab antibodies with activity of uveitis in juvenile idiopathic arthritis-related uveitis.
METHODS:
This was a retrospective observational case series in a clinical setting at the Department of Ophthalmology, Helsinki University Hospital, Finland in 2014-2016. Thirty-one paediatric patients with chronic anterior juvenile idiopathic arthritis-related uveitis in 58 eyes and who had been on adalimumab ≥6 months were eligible for the study. Uveitis activity during adalimumab treatment, adalimumab trough levels and anti-adalimumab antibody levels were recorded.
RESULTS:
Anti-adalimumab antibody levels ≥12 AU /ml were detected in nine patients (29%). This level of anti-adalimumab antibodies was associated with a higher grade of uveitis (p<0.001), uveitis that was not in remission (p=0.001) and with lack of concomitant methotrexate therapy (p=0.043). In patients with anti-adalimumab antibody levels <12 AU/ml, higher serum trough levels did not associate with better control of uveitis (p=0.86).
CONCLUSIONS:
Adalimumab treatment might be better guided by monitoring anti-adalimumab antibody formation in treating JIA-related uveitis.

PMID: 29148422 [PubMed]

Received: 28/07/2016 - Accepted : 14/12/2016 - In Press: 14/11/2017 - Published: 12/12/2017